Category 'Antibodies'

  1. Further evidence shows why you must ALWAYS validate antibodies!

    We recently blogged about validating your antibodies, and a lot of you got in touch to share your experiences and also suggest another study we should feature here on our blog. Our last validation blog pointed out that while our team here at CiteAb aims to help you find the best potential antibodies for your […]

  2. What are the most important antibody targets for immunocytochemistry?

    New to our series of blogs on antibody research applications, today we are exploring the top targets for ICC, or immunocytochemistry. ICC is the staining and microscopic examination of cells, which are often grown in culture. This is not to be confused with immunohistochemistry (IHC), which involves the staining of tissues with their normal organisation […]

  3. New antibody against Zika

    You’ve likely seen the great deal of coverage the media has been giving to the Zika virus recently – and here at CiteAb we have just listed our first anti-Zika antibody for use in research. Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitos, causing symptoms similar to the flu which […]

  4. Do you need custom antibodies?

    We have a number of new suppliers available on our Custom Antibody Listing, and we thought we would tell you a bit about our Custom Antibody Listing feature and about these new companies. The Custom Antibody Listing is the area of CiteAb dedicated to companies who provide custom affinity reagent services, including the production of custom antibodies, […]

  5. Should all research antibodies be recombinant monoclonals? Too early to ditch polyclonals!

    An article published today in Nature calls for the large scale production of recombinant monoclonal antibodies, along with other recombinant affinity reagents including aptamers and affimers, for use in the research market. Andrew Bradbury and Andreas Pluckthun argue that this would lead to increased reproducibility and promote progress in biomedical research. Here at CiteAb we […]

  6. CRISPR/Cas9 antibodies now available – they’re like buses….

    Gene editing using the CRISPR-Cas system has generated tremendous excitement and promises to revolutionise many aspects of bioscience research. If you’ve not seen it already, do have a look at our introductory guide to CRISPR-Cas. A PubMed search reveals over 1000 publications which mention CRISPR but until recently there were no commercial antibodies to Cas9, […]

  7. Starting your PhD? Here are our tips for finding an antibody.

    Starting a PhD is tough – it takes a while to get used to a new campus, new colleagues and a new beginning. If you’re working in the life sciences, chances are you’re going to be using antibodies in your research. You’ll probably be asked by your supervisor to find suitable antibodies, so I, Dr […]

  8. Call for antibodies: Ebola

    We’re all very aware of the current heightened concern over the spread of Ebola, with the World Health Organisation confirming that 1,069 people have been killed by the virus in West Africa. First isolated in 1976 during outbreaks of an unidentified viral haemorrhagic fever in southern Sudan and northern Democratic Republic of the Congo (formerly […]

  9. Aptamer, from the Latin aptus

    Here at CiteAb we’re always interested to hear of any new developments in the world of affinity reagents and this week we’re taking a look at aptamers. While aptamers aren’t exactly new arrivals to the affinity reagent party, we are now beginning to see companies pop up that provide catalogue aptamers rather than custom designed […]

  10. How do I cite the antibodies I use?

    Whats the problem? So you’ve found the antibodies you need for your experiments (hopefully using CiteAb!), they helped you get some great results and now you’re ready to write your paper. How do you report the antibodies you used, it should be easy right? Perhaps not! What is surprising is that less than half of […]